Management of Atopic Dermatitis During the COVID-19 Pandemic: Key Questions and Review of the Current Evidence

Po Chien Wu*, Chia Lun Li, Yun Ting Chang, Chih Chiang Chen, Chen Yi Wu, Sheng Hsiang Ma*

*此作品的通信作者

研究成果: Review article同行評審

摘要

Abstract: Since the outbreak of COVID-19, management of atopic dermatitis (AD) has been widely discussed. Key issues include the risk of COVID-19 infection and related outcomes in AD patients, the efficacy and safety of COVID-19 vaccination in AD populations, and management of AD in the COVID-19 pandemic. Recent studies have shown that patients with AD have a slightly increased risk of COVID-19 infection but are not associated with a worse outcome than the non-AD population. COVID-19 vaccination is generally effective and safe in patients with AD. However, temporary discontinuation of certain systemic immunomodulatory agents after vaccination is suggested. During the pandemic, continuation of all immunomodulating agents is suggested, but these agents should be paused when patients with AD are infected with COVID-19 until recovery. Further studies are warranted to investigate the long-term interaction between AD and COVID-19 to aid clinical decisions during the pandemic.

原文English
頁(從 - 到)77-84
頁數8
期刊Dermatitis
34
發行號2
DOIs
出版狀態Published - 1 3月 2023

指紋

深入研究「Management of Atopic Dermatitis During the COVID-19 Pandemic: Key Questions and Review of the Current Evidence」主題。共同形成了獨特的指紋。

引用此